rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VRDN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans - Slideshow

      2026-11-13. The following slide deck was published by Viridian Therapeutics, Inc.

      Nov 13Seeking AlphaVRDN
      Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
      Nov 9BenzingaVRDN
      Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
      Nov 9Yahoo FinanceVRDN
      Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
      Nov 8Yahoo FinanceVRDN
      Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
      Nov 6Yahoo FinanceVRDN
      What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinanceVRDN
      Stifel raises Viridian Therapeutic stock price target on strong Lumvoa launch
      Nov 4Investing.comVRDN
      Viridian Therapeutics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaVRDN
      Viridian Therapeutics earnings beat by $0.21, revenue topped estimates
      Nov 4Investing.comVRDN
      Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceVRDN
      Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
      Nov 4Yahoo FinanceVRDN
      How FDA Approval Will Impact Viridian Therapeutics Stock
      Oct 27Yahoo FinanceVRDN
      Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
      Oct 17Yahoo FinanceVRDN
      RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

      Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailVRDN
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailVRDN
      Weekly Note: Revisiting Viridian Therapeutics: Two Shots At An IGF-1R Franchise, Priced For One (NASDAQ:VRDN)

      PHVS, UNCY, BHVN, CYTK, KURA, GRCE, INSM, RARE, CELC, RCKT_________________________________________________BUY | 12-month price target $31 (+51%) | Lumvoa...

      Sep 27Seeking AlphaVRDN
      Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

      Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark

      Sep 22Yahoo FinanceVRDN
      Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN)

      Viridian Therapeutics aims to leverage its infrastructure for both Lumvoa and elegrobart, potentially improving franchise economics. Read more on VRDN.

      Sep 17Seeking AlphaVRDN
      Sling Therapeutics raises $123 million to advance thyroid eye disease drug
      Sep 16ReutersVRDN
      Viridian at Wells Fargo conference: launch gains and pipeline build
      Sep 8Investing.comVRDNWFC
      Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
      Sep 3BenzingaCLRBVRDN
      Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
      Sep 2Yahoo FinanceVRDNWFC

      This is the newest page. Registered accounts read further back.